{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit was not calculable because an insufficient number of participants reached the event at the final time point for assessment","groupId":"OG000","lowerLimit":"1.1","upperLimit":"NA","value":"3.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Duration of response (DOR) is defined as the time from first documentation of response (CR, VGPR or PR) to disease progression. The median DOR with 95% CI was estimated using the Kaplan Meier method","dispersionType":"95% Confidence Interval","groups":[{"description":"Thalidomide (Thal) + Zolendronic acid (ZLD)","id":"OG000","title":"Arm I: Thal/ZLD"},{"description":"Zoledronic acid (ZLD)","id":"OG001","title":"Arm II: ZLD"}],"paramType":"MEDIAN","populationDescription":"Participants who achieved a confirmed response (CR, VGPR, or PR) as described above were analyzed.","reportingStatus":"POSTED","timeFrame":"time from start of response to progression (up to 5 years)","title":"Duration of Response (Complete Response, Partial Response, and Very Good Partial Response)","type":"SECONDARY","unitOfMeasure":"years"}